Related Experiment Video
Updated: Oct 29, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.7K
Oligometastatic non-small cell lung cancer: Current management
Alicia Román-Jobacho1, María Hernández-Miguel2, María Jesús García-Anaya1
1Department of Radiation Oncology, Hospital Virgen de la Victoria, Málaga, Spain.
Journal of Clinical and Translational Research
|July 9, 2021
Summary
Aggressive radiotherapy, such as stereotactic body radiation therapy (SBRT), offers improved survival for select non-small cell lung cancer (NSCLC) patients with oligometastases. This minimally invasive option provides an alternative to surgery, especially for fragile patients.
Area of Science:
- Oncology
- Radiation Oncology
- Pulmonology
Background:
- Oligometastatic non-small cell lung cancer (NSCLC) affects 20%-50% of patients at diagnosis.
- Recent advancements enable aggressive local therapies, improving survival for this patient group.
- Minimally invasive techniques like SBRT offer effective local control with fewer side effects than surgery.
Purpose of the Study:
- To review current evidence on managing oligometastatic NSCLC.
- To highlight the significant role of radiotherapy in treatment strategies.
Main Methods:
- Review of recent clinical evidence, including Phase I and II trials.
- Focus on systemic therapy, surgery, and advanced radiotherapy techniques (SRS/SBRT).
Main Results:
- Systemic therapy is the initial recommendation, followed by radical treatment of primary tumor and metastases.
- Phase II trials show improved progression-free survival (PFS) with aggressive local therapy in selected patients.
- Radiotherapy combined with immunotherapy demonstrates potential for improved tumor response and overall survival.
Conclusions:
- Aggressive local therapies, including SBRT, are justified for selected oligometastatic NSCLC patients.
- Consideration for radical treatment, potentially combined with systemic therapy or immunotherapy, is recommended.
- Enrollment in ongoing clinical trials is encouraged for patients with oligometastatic NSCLC.
